Ovid Therapeutics has finished the long unwind of its soticlestat royalty story and is now a two-mechanism clinical company funded through the end of the decade. A vehicle advised by Perceptive Advisors took global rights to that older epilepsy asset from Ovid and Takeda, leaving Ovid with equity, contingent milestones, and a residual royalty after Ligand's contractual cut. The investment debate is no longer whether Takeda's failed late-stage program returns as a cash engine. It is whether the next year of human data on a next-generation GABA-aminotransferase inhibitor and a first oral potassium-chloride cotransporter activator can justify a mid-cap central-nervous-system valuation built almost entirely on cash and optionality.
The financing that made this reset possible arrived in two waves. A March private placement brought $60 million of gross proceeds to expand the seizure program into tuberous sclerosis and infantile spasms. Series A warrants from the prior-year raise then expired in April and converted almost entirely into common stock and pre-funded warrants, adding another $54 million. Cash and marketable securities sat near $170 million at mid-year, which management frames as runway into 2029. That is a long clock for a company whose lead human evidence is still healthy-volunteer pharmacology, not patient seizure reduction.
Operating spend is already rising as both programs enter or expand clinical work. Research and development reached $10 million in the June quarter, and first-half operating cash burn was $32 million. License revenue collapsed because last year's Takeda-related items did not repeat. The photosensitivity readout near year-end is the first patient-adjacent test of the seizure program. Does a clean signal there, plus a tolerable oral transporter Phase One package, re-rate a company that still has no product sales?